Fertilcrol

What Fertilcrol can do for you?

SleepRex contain MELATONIN, many adults experience frequent or occasional sleep disturbance, including difficulty falling asleep, staying asleep, or waking too early. The most popular natural sleep aid is melatonin because it is effective and safe to use.

The human body has a “biological clock,” a small region near the centre of the brain called the suprachiasmatic nucleus (SCN) that regulates sleeping, waking, and other body processes. During conditions of dim light, such as at nightfall, special photoreceptors in the eyes send signals to the SCN, which forwards the signal to the pineal gland, causing it to release melatonin into the bloodstream. Melatonin prepares the body for sleep by inducing drowsiness and lowering body temperature. When sufficient light returns, such as at dawn, the SCN signals the pineal gland to stop releasing melatonin and the body returns to a waking state.

But the rhythm of the internal clock can be disrupted due to shift work, jet lag, stress, delayed sleep phase syndrome, or other factors, leaving the body with insufficient melatonin at bedtime. Melatonin production also declines with age. Insufficient melatonin causes sleep disturbance.

Combining treatment with Myo-Inositol and D-Chiro-Inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients

Polycystic ovary syndrome (PCOS), a relevant cause of infertility, is a heterogeneous, endocrine disorder affecting up to 10–15% of women in reproductive age. Besides hyperandrogenism, insulin resistance (IR) plays a key role in such syndrome. Insulin-sensitizing drugs, such as Metformin, are effective in treating hyper-insulinemic PCOS patients. Recently, inositols – myo-inositol (MI) and D-chiro-inositol (DCI) – have shown to be an efficient and safe alternative in PCOS management, as both inositol isoforms are able to counteract downstream consequences of insulin resistance. Yet, whereas DCI contributes in mediating insulin activity mainly on non-ovarian tissues, MI displays specific effects on ovary, chiefly by modulating glucose metabolism and FSH-signaling. Moreover, MI may also improve ovarian functions by modulating steroid metabolism through non-insulin-dependent pathways. As DCI and MI activity likely involves different biological mechanisms, both inositol isoforms can be synergistically integrated according to a multitargeted design, by combining MI and DCI in a ratio corresponding to their physiological plasma relative amount (40:1). New experimental and clinical evidence with MI plus DCI evidenced the suitability of such integrated approach, and provided promising results. Further studies need to investigate thoroughly the molecular mechanism and confirm such preliminary data.